key: cord-0976344-ck4fw84g
authors: Malinis, Maricar; Cohen, Elizabeth; Azar, Marwan M.
title: Effectiveness of SARS‐CoV‐2 vaccination in fully‐vaccinated solid organ transplant recipients
date: 2021-06-08
journal: Am J Transplant
DOI: 10.1111/ajt.16713
sha: 0485fc9da430f2b0ca34d30a4265e18eabd023d4
doc_id: 976344
cord_uid: ck4fw84g

The COVID‐19 pandemic has disproportionately impacted immunosuppressed patients, including solid organ transplant recipients (SOTR). COVID‐19‐associated mortality among SOTR was estimated at 20.5% in the early phase of the pandemic(1). SARS‐CoV‐2 vaccination may help reduce the morbidity and mortality of COVID‐19 among SOTR. Under emergency use authorization, the US Food Drug Administration approved two SARS‐CoV‐2 messenger RNA vaccines [BNT162b2 (Pfizer), mRNA‐1273 (Moderna)] and an adenovirus vector‐based vaccine [Ad26.COV2.S (Johnson and Johnson)].

vaccine ( Figure 1 ). Three-hundred and twenty-four (58%) and 206 (37%) SOTR received ≥1 dose of BNT162b2 and mRNA-1273, respectively. Twenty-seven (5%) SOTR received Ad26.COV2.S. Four hundred and eighty-two SOTR (86%) completed vaccination and 459 (82%) were fully vaccinated (i.e., ≥14 days post-completion of vaccine series). Of those who received ≥1 dose, 9 (1.6%) tested positive using SARS-CoV-2 nucleic acid amplification testing (NAAT) post-vaccination. Six of 98 (6.12%) partially vaccinated SOTR developed SARS-CoV-2 infection. Breakthrough infection, defined as positive SARS-CoV-2 NAAT ≥14 days post-vaccine series completion, occurred in 3 of 459 (0.65%) fully vaccinated SOTR (Supplement Table 2 ). Clinical characteristics of the SOTR who developed SARS-CoV-2 infection post-vaccination are summarized in Table 1 . All three had mild COVID-19, received bamlanivimab/etesevimab, and survived. Only one (patient 8) had an available cycle threshold, which was reported 15.5 and was hospitalized for a reason unrelated to COVID-19. 

Additional supporting information may be found online in the Supporting Information section at the end of the article.

This article is protected by copyright. All rights reserved 

COVID-19 in solid organ transplant: A multi-center cohort study

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19